|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Ezetimibe]] |
| {{Ezetimibe}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Overdosage==
| |
| In clinical studies, administration of ezetimibe, 50 mg/day to 15 healthy subjects for up to 14 days, 40 mg/day to 18 patients with primary [[hyperlipidemia]] for up to 56 days, and 40 mg/day to 27 patients with [[homozygous sitosterolemia]] for 26 weeks was generally well tolerated. One female patient with [[homozygous sitosterolemia ]]took an accidental overdose of ezetimibe 120 mg/day for 28 days with no reported clinical or laboratory adverse events.
| |
| | |
| In the event of an overdose, symptomatic and supportive measures should be employed.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ZETIA (EZETIMIBE) TABLET [MERCK SHARP & DOHME CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a773b0b2-d31c-4ff4-b9e8-1eb2d3a4d62a | publisher = | date = | accessdate = 11 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Hypolipidemic agents]]
| |
| [[Category:Lactams]]
| |
| [[Category:Merck]]
| |
| [[Category:Schering-Plough]]
| |
| [[Category:Azetidines]]
| |
| [[Category:Organofluorides]]
| |
| [[Category:Phenols]]
| |
| [[Category:Cardiovasuclar Drugs]]
| |
| [[Category:Drugs]]
| |